BioAtla, Inc. (BCAB)

US — Healthcare Sector
Peers: PMVP  CCCC  NAUT  IPSC  PASG  IKNA  OLMA  AVTE  ADAG  ACRV  RZLT  ANTX  GRCL  THRX  GLUE  DSGN  ERAS  FHTX  STTK  KYMR  NRIX 

Automate Your Wheel Strategy on BCAB

With Tiblio's Option Bot, you can configure your own wheel strategy including BCAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BCAB
  • Rev/Share 0.1888
  • Book/Share 0.0094
  • PB 43.5538
  • Debt/Equity 1.0128
  • CurrentRatio 2.3452
  • ROIC -2.9381

 

  • MktCap 23893003.0
  • FreeCF/Share -0.9854
  • PFCF -0.4163
  • PE -0.385
  • Debt/Assets 0.0145
  • DivYield 0
  • ROE -3.5792

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
BCAB
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA) SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment …

Read More
image for news BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
BCAB
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral

BioAtla, Inc. (NASDAQ:BCAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Jeet Mukherjee – BTIG Reni Benjamin - Citizens JMP Arthur He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla First Quarter 2025 Earnings Call.

Read More
image for news BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
BCAB
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26–29, 2025 and in Scottsdale, AZ from March 27–29, 2025, respectively.

Read More
image for news BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

About BioAtla, Inc. (BCAB)

  • IPO Date 2020-12-16
  • Website https://www.bioatla.com
  • Industry Biotechnology
  • CEO Dr. Jay M. Short Ph.D.
  • Employees 61

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.